Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. Diamyd Medical AB (publ) was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. The company was founded in 1984 and is headquartered in Stockholm, Sweden.
Frequently asked questions
What sector does Diamyd Medical AB (publ) (DMN) operate in?
Diamyd Medical AB (publ) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Diamyd Medical AB (publ) (DMN) current stock price?
As of the latest data, Diamyd Medical AB (publ) stock price is €0.07, with a previous close of €0.07. Diamyd Medical AB (publ) lost -€0.00 in the last trading session, representing a -1.41% loss.
What is Diamyd Medical AB (publ) (DMN) current market capitalization?
Diamyd Medical AB (publ) market cap is approximately 10.57 million.
What is Diamyd Medical AB (publ) (DMN) Earnings Per Share (EPS)?
The trailing EPS is -€0.18.
What is Diamyd Medical AB (publ) (DMN) EBITDA?
Diamyd Medical AB (publ) EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -11.52 million.
Does Diamyd Medical AB (publ) (DMN) pay dividends?
No. Diamyd Medical AB (publ) does not pay a dividend.
What is Diamyd Medical AB (publ) (DMN) beta (volatility) score?
Diamyd Medical AB (publ) has a beta of 2.289, indicating very high volatility compared to the market.
